{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:11:59Z","timestamp":1789841519612,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of locally advanced and metastatic gastrointestinal stromal tumours (GISTs). Patients are experiencing prolonged survival but often at the expense of their health-related quality of life. It is not only the physical side effects that impact GIST patients\u2019 daily lives but also the psychological and social challenges they have to deal with. This qualitative study aimed to explore the psychological and social life challenges of GIST patients with locally advanced and metastatic disease on \u2265 5 years TKI treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Semi-structured interviews with 15 locally advanced and\/or metastatic GIST patients and 10 medical oncologists with experience of delivering care to this specific patient group were conducted. Thematic analysis was used to interpret the data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Psychological challenges expressed by participants concerned fears, scanxiety, negative change in emotion and mood, doubts about their treatment and follow-up, living with uncertainty, lack of understanding from others or healthcare professionals, and constantly being reminded of their illness. Challenges regarding social health included financial difficulties, challenges in relationships, concerns about fertility and parenting, work, and impact on social activities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The reported psychological and social challenges can significantly hamper the overall quality of life of GIST patients. Some challenges were clearly underreported and hardly recognized by medical oncologist, as they may tend to focus on the physical side effects and clinical outcomes of treatment. Therefore, it is essential to take the patient\u2019s perspective into account in research and clinical practice to ensure optimal care for this patient group.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-07810-7","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T08:02:26Z","timestamp":1685088146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: a qualitative study with patients and medical oncologists"],"prefix":"10.1007","volume":"31","author":[{"given":"Deborah","family":"van de Wal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Fauske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind S.","family":"Bruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winette T. A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Husson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"7810_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K S\u00f8reide","year":"2016","unstructured":"S\u00f8reide K, Sandvik OM, S\u00f8reide JA, Giljaca V, Jureckova A, Bulusu VR (2016) Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol 40:39\u201346","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"7810_CR2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/bjs.10809","volume":"105","author":"WTA Van Der Graaf","year":"2018","unstructured":"Van Der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, De Wilt JHW (2018) Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. Br J Surg 105(8):1020\u20131027","journal-title":"Br J Surg"},{"issue":"4","key":"7810_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Demetri GD, Von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620\u2013625","journal-title":"J Clin Oncol"},{"issue":"15","key":"7810_CR4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1200\/JCO.2016.71.0228","volume":"35","author":"PG Casali","year":"2017","unstructured":"Casali PG, Zalcberg J, Le Cesne A et al (2017) Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. J Clin Oncol 35(15):1713\u20131720","journal-title":"J Clin Oncol"},{"issue":"1","key":"7810_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"P Casali","year":"2022","unstructured":"Casali P, Blay J, Abecassis N et al (2022) Gastrointestinal stromal tumours: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 33(1):20\u201333","journal-title":"Ann Oncol"},{"issue":"3","key":"7810_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/bmjspcare-2012-000200","volume":"2","author":"C Harley","year":"2012","unstructured":"Harley C, Pini S, Bartlett YK, Velikova G (2012) Defining chronic cancer: patient experiences and self-management needs. BMJ Support Palliat Care 2(3):248\u2013255","journal-title":"BMJ Support Palliat Care"},{"issue":"1","key":"7810_CR7","doi-asserted-by":"publisher","first-page":"e042404","DOI":"10.1136\/bmjopen-2020-042404","volume":"11","author":"EEM Kolsteren","year":"2021","unstructured":"Kolsteren EEM, Deuning-Smit E, Prins JB et al (2021) Psychological aspects in patients with advanced cancer receiving lifelong systemic treatment: protocol for a scoping review. BMJ Open 11(1):e042404","journal-title":"BMJ Open"},{"issue":"8","key":"7810_CR8","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3109\/0284186X.2014.1003960","volume":"54","author":"JA Custers","year":"2015","unstructured":"Custers JA, Tielen R, Prins JB, De Wilt JH, Gielissen MF, Van Der Graaf WT (2015) Fear of progression in patients with gastrointestinal stromal tumors (GIST): is extended lifetime related to the Sword of Damocles? Acta Oncol 54(8):1202\u20131208","journal-title":"Acta Oncol"},{"issue":"6","key":"7810_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1370\/afm.245","volume":"2","author":"F Borrell-Carri\u00f3","year":"2004","unstructured":"Borrell-Carri\u00f3 F, Suchman AL, Epstein RM (2004) The biopsychosocial model 25 years later: principles, practice, and scientific inquiry. Ann Fam Med 2(6):576\u2013582","journal-title":"Ann Fam Med"},{"issue":"7","key":"7810_CR10","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3390\/cancers14071832","volume":"14","author":"D Van De Wal","year":"2022","unstructured":"Van De Wal D, Elie M, Le Cesne A et al (2022) Health-related quality of life and side effects in gastrointestinal stromal tumor (GIST) patients treated with tyrosine kinase inhibitors: a systematic review of the literature. Cancers (Basel) 14(7):1832","journal-title":"Cancers (Basel)"},{"key":"7810_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13569-019-0116-3","volume":"9","author":"L Fauske","year":"2019","unstructured":"Fauske L, Hompland I, Lorem G, Bondevik H, Bruland \u00d8S (2019) Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study. Clin Sarcoma Res 9:6","journal-title":"Clin Sarcoma Res"},{"key":"7810_CR12","doi-asserted-by":"publisher","first-page":"1814394","DOI":"10.1155\/2020\/1814394","volume":"2020","author":"L Fauske","year":"2020","unstructured":"Fauske L, Hompland I, Lorem G, Hall KS, Bondevik H (2020) Striving towards normality in daily life: a qualitative study of patients living with metastatic gastrointestinal stromal tumour in long-term clinical remission. Sarcoma 2020:1814394\u20131814394","journal-title":"Sarcoma"},{"issue":"4","key":"7810_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/fon-2022-0730","volume":"19","author":"D van de Wal","year":"2023","unstructured":"van de Wal D, Venkatesan S, Benson C (2023) A patient\u2019s perspective on the side effects of tyrosine kinase inhibitors in the treatment of advanced and metastatic gastrointestinal stromal tumors. Future Oncol 19(4):299\u2013314. https:\/\/doi.org\/10.2217\/fon-2022-0730","journal-title":"Future Oncol"},{"key":"7810_CR14","unstructured":"NVivo (released in March 2020). https:\/\/www.qsrinternational.com\/nvivo-qualitative-data-analysis-software\/home"},{"key":"7810_CR15","doi-asserted-by":"publisher","first-page":"26152","DOI":"10.3402\/qhw.v9.26152","volume":"9","author":"V Braun","year":"2014","unstructured":"Braun V, Clarke V (2014) What can \"thematic analysis\" offer health and wellbeing researchers? Int J Qual Stud Health Well Being 9:26152\u201326152","journal-title":"Int J Qual Stud Health Well Being"},{"issue":"7","key":"7810_CR16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","volume":"22","author":"PG Kluetz","year":"2016","unstructured":"Kluetz PG, Slagle A, Papadopoulos EJ et al (2016) Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res 22(7):1553\u20131558","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7810_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19(6):349\u2013357","journal-title":"Int J Qual Health Care"},{"issue":"24","key":"7810_CR18","first-page":"56","volume":"177","author":"B Feiler","year":"2011","unstructured":"Feiler B (2011) Scanxiety. Fear of a postcancer ritual. Time 177(24):56\u201356","journal-title":"Time"},{"issue":"29","key":"7810_CR19","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1200\/JCO.2017.72.8212","volume":"35","author":"B Thewes","year":"2017","unstructured":"Thewes B, Husson O, Poort H et al (2017) Fear of cancer recurrence in an era of personalized medicine. J Clin Oncol 35(29):3275\u20133278","journal-title":"J Clin Oncol"},{"key":"7810_CR20","first-page":"253","volume":"6","author":"N Macdonald","year":"2012","unstructured":"Macdonald N, Shapiro A, Bender C, Paolantonio M, Coombs J (2012) Experiences and perspectives on the GIST patient journey. Patient Prefer Adherence 6:253\u2013262","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"7810_CR21","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1002\/cam4.3889","volume":"10","author":"C JaE","year":"2021","unstructured":"JaE C, Davis L, Messiou C, Prins JB, Van Der Graaf WTA (2021) The patient perspective in the era of personalized medicine: what about scanxiety? Cancer Med 10(9):2943\u20132945","journal-title":"Cancer Med"},{"key":"7810_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.lungcan.2016.08.002","volume":"100","author":"JM Bauml","year":"2016","unstructured":"Bauml JM, Troxel A, Epperson CN et al (2016) Scan-associated distress in lung cancer: Quantifying the impact of \"scanxiety\". Lung Cancer 100:110\u2013113","journal-title":"Lung Cancer"},{"issue":"12","key":"7810_CR23","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.1007\/s00520-021-06319-1","volume":"29","author":"KT Bui","year":"2021","unstructured":"Bui KT, Blinman P, Kiely BE, Brown C, Dhillon HM (2021) Experiences with scans and scanxiety in people with advanced cancer: a qualitative study. Support Care Cancer 29(12):7441\u20137449","journal-title":"Support Care Cancer"},{"issue":"2","key":"7810_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","volume":"12","author":"AJ Mitchell","year":"2011","unstructured":"Mitchell AJ, Chan M, Bhatti H et al (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12(2):160\u2013174","journal-title":"Lancet Oncol"},{"issue":"2","key":"7810_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/ije\/dyu038","volume":"43","author":"Z Steel","year":"2014","unstructured":"Steel Z, Marnane C, Iranpour C et al (2014) The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013. Int J Epidemiol 43(2):476\u2013493","journal-title":"Int J Epidemiol"},{"issue":"4","key":"7810_CR26","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.1998.16.4.1594","volume":"16","author":"SD Passik","year":"1998","unstructured":"Passik SD, Dugan W, Mcdonald MV, Rosenfeld B, Theobald DE, Edgerton S (1998) Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 16(4):1594\u20131600","journal-title":"J Clin Oncol"},{"key":"7810_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13569-019-0124-3","volume":"10","author":"I Hompland","year":"2020","unstructured":"Hompland I, Fauske L, Lorem GF, Bruland \u00d8S (2020) Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors. Clin Sarcoma Res 10:2","journal-title":"Clin Sarcoma Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07810-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07810-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07810-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T09:09:28Z","timestamp":1686388168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07810-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["7810"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07810-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the by the NKI-AVL Institutional Review Board (No. IRBd20-083, date 19-01-2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"352"}}